Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03973437
Other study ID # 2019-SDU-QILU-G002
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2019
Est. completion date June 1, 2020

Study information

Verified date June 2019
Source Shandong University
Contact Xiuli Zuo, MD,PhD
Phone 15588818685
Email zuoxiuli@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop an artificial intelligence(AI) assisted scoring system, which can evaluate the disease severity and mucosal healing stage in patients with ulcerative colitis. Then testify whether this new scoring system can help physicians to enhance the accuracy of disease severity assessments in a multi-center clinical practice.


Description:

Ulcerative colitis is a non-specific chronic inflammation of gut characterized by referral bloody stool, diarrhea and abdominal pain. Endoscopic features of the disease severity and mucosal healing stage are strongly associated with treatment response and prognosis in the future. Currently, the Mayo endoscopic sub-score (Mayo ES) and Ulcerative colitis endoscopic index of severity (UCEIS) are commonly recommended to guide therapeutic adjustments. However, the accuracy of these scales greatly relies on intra-observer and inter-observer consistency for lack of objective measurements. Recently, deep learning algorithm based on convolutional neural network (CNN) has shown multiple potential in computer-aided detection and computer-aided diagnose of gastrointestinal lesions. Up to now, no randomized controlled trials have been conducted to evaluate the performance of deep learning algorithm for assessing disease activity in ulcerative colitis. This study aims to train a deep learnig algorithm to assess severity and mucosal healing stage of ulcerative colitis using the Mayo ES and UCEIS scale, then testify whether the engagement of AI can improve the evaluation accuracy of physicians in a multi-center clinical practice.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date June 1, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients with ulcerative colitis undergoing colonoscopy

Exclusion Criteria:

- Known or suspected bowel obstruction, stricture or perforation

- Compromised swallowing reflex or mental status

- Severe congestive heart failure (New York Heart Association class III or IV)

- Uncontrolled hypertension (systolic blood pressure > 170 mm Hg, diastolic blood pressure > 100 mm Hg)

- Pregnancy or lactation

- Hemodynamically unstable

- Colonic surgery history

- Bad bowel preparation (segmental BBPS<2)

- Unable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Artificial inteligence associated ulcerative colitis severity scoring system
Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
Conventional human scoring
Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.

Locations

Country Name City State
China Qilu hosipital Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The scoring accuracy of Mayo ES in AI-associated group and conventional group. The scoring accuracy of Mayo endoscopic sub-score (Mayo ES) in each group will be calculated using scores from expert group as reference standard. The Mayo ES is a 4-point scale, which classifies the endoscopic severity of ulcerative colitis into the following four categories: point 0 refers to normal or inactive disease, point 1 refers to mild disease with erythema, decreased vascular patterns and mild friability, point 2 refers to moderate disease with marked erythema, absence of vascular patterns, friability and erosions, point 3 refers to severe disease with spontaneous bleed and ulceration. The scoring accuracy of Mayo ES ranging from 0 to 3 point will be separately evaluated in both groups. 6 months
Primary The scoring accuracy of UCEIS in AI-associated group and conventional group. The scoring accuracy of Ulcerative colitis endoscopic index of severity (UCEIS) in each group will be separately calculated using scores from expert group as reference standard. The UCEIS is an 8-point scale consists of 3 parts: vascular pattern (point 0 refers to normal mucosa, point 1 refers to patchy obliteration of vascular pattern, point 2 refers to complete obliteration of vascular pattern), bleeding (point 0 refers to no visible blood, point 1 refers to some spots of coagulated blood, point 2 refers to free liquid, point 3 refers to frank blood in the lumen), erosions and ulcers (point 0 refers to normal mucosa, point 1 refers to erosions, point 2 refers to superficial ulcers, point 3 refers to deep ulcers. The total UCEIS score summarized by the above 3 parts will be analyzed. The scoring accuracy of UCEIS ranging from 0 to 8 point will be separately evaluated in both group. 6 months
Secondary The accuracy of mucosal healing judgements using Mayo ES in each group. The accuracy of mucosal healing judgements using Mayo ES will be calculated in each group. Assessments from expert group will be used as reference standard. Complete mucosal healing is defined as point 0 in Mayo ES scale, which refers to normal or inactive disease. 6 months
Secondary The accuracy of mucosal healing judgements using UCEIS in each group. The accuracy of mucosal healing judgements using UCEIS will also be calculated in each group. Assessments from expert group will be used as reference standard. Complete mucosal healing is defined as point 0 in UCEIS scale, which refers to normal vascular pattern without bleeding, erosions and ulceration. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2